Indivior Pharmaceuticals, Inc. Proceeds from Long-Term Debt Issued
Indivior Pharmaceuticals, Inc. (INDV) reported Proceeds from Long-Term Debt Issued of $489.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00.
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $489.00M.
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2025-06-30 was $0.00.
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $0.00.
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2024 was $332.00M.
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2023 was $0.00.
- Indivior Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $489.00M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $489.00M 10-Q · filed 2026-04-30 | ||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $0.00 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | ||
| 2024-12-31 | $332.00M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |